Boston Scientific Shares Fall After Q1 Outlook Misses Despite Strong Q4 Results

Overview

• Boston Scientific posted Q4 adjusted earnings of $0.80 per share versus $0.78 expected, with net sales of $5.29 billion and 12.7% organic growth.
• The company guided Q1 organic growth to 8.5%–10% versus analysts’ 9.8% view and projected adjusted EPS of $0.78–$0.80.
• Electrophysiology revenue reached $890 million, missing the $933 million consensus, with the shortfall concentrated in the U.S. market.
• A roughly 9.3% quarterly tax rate, below Stifel’s modeled 13.5%, boosted reported earnings and clouded the quality of the beat.
• Shares fell about 8.4% in premarket trading as the company reiterated full-year guidance of $3.43–$3.49 in adjusted EPS and 10%–11% organic growth, implying a later-year pickup after a slower Q1.